How Does Ozempic Cause Gastroparesis? Symptoms and Risk Factors Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Specific Risks

If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be wondering whether these symptoms point to gastroparesis. Building on decades of research into medication side effects, this page explains the known risk factors and diagnostic steps for Ozempic-related gastroparesis.

Understanding Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Its mechanism of action includes slowing gastric emptying, which is a therapeutic effect but also a potential source of adverse gastrointestinal events. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has emerged as a significant concern in clinical practice and litigation. Clinical presentation of gastroparesis includes early satiety, postprandial fullness, nausea, vomiting, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy showing delayed emptying. The condition can severely impair quality of life and lead to malnutrition, dehydration, and metabolic disturbances. In the context of Ozempic use, the drug's pharmacological effect on gastric motility may exacerbate or unmask underlying gastroparesis, or in some cases, induce it de novo. Evidence from the Ozempic prescribing information indicates that gastrointestinal adverse reactions are common. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data demonstrate a dose-dependent increase in gastrointestinal side effects. Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these are not specifically labeled as gastroparesis, they are consistent with the spectrum of delayed gastric emptying.

Mechanisms and Clinical Evidence

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying by inhibiting vagal nerve activity and reducing antral contractions. This effect is intended to improve postprandial glycemic control but can become pathological in susceptible individuals. Prolonged use may lead to sustained impairment of gastric motility, potentially resulting in gastroparesis. The timeline between exposure and documented harm varies; some patients develop symptoms during dose escalation, while others may experience onset after months of treatment. The prescribing information notes that the majority of nausea, vomiting, and diarrhea occurred during dose escalation, but chronic symptoms may persist or worsen over time. Regarding adequacy of warnings, the Ozempic label does not explicitly list gastroparesis as a warning or precaution. The label includes a section on hypersensitivity reactions, noting serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, it does not specifically address the risk of gastroparesis. This omission may be relevant in litigation, as patients and prescribers may not have been adequately informed about the potential for this serious adverse effect.

Settlement Criteria and Legal Considerations

Settlement-related considerations for affected patients include documenting a clear temporal relationship between Ozempic use and the onset of gastroparesis symptoms. Key factors include the timing of symptom onset relative to drug initiation and dose escalation, the absence of other causes (e.g., diabetes-related autonomic neuropathy, prior gastric surgery, or other medications), and objective evidence of delayed gastric emptying via gastric emptying scintigraphy. Patients who discontinued Ozempic due to gastrointestinal adverse reactions and subsequently developed chronic gastroparesis may have stronger claims. The discontinuation rates in clinical trials (3.1% for 0.5 mg and 3.8% for 1 mg) indicate that a subset of patients experienced intolerable gastrointestinal effects (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In summary, the evidence supports a plausible link between Ozempic use and gastroparesis, mediated by the drug's effect on gastric emptying. The prescribing information documents a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, but does not explicitly warn of this condition. Patients who develop gastroparesis after Ozempic exposure should seek medical evaluation and legal counsel to assess potential claims. The timeline between exposure and harm, along with the adequacy of warnings, are central to settlement criteria.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to or worsen gastroparesis in some patients. Clinical trials show a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, though the label does not explicitly warn of this condition. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

What are the criteria for an Ozempic gastroparesis lawsuit settlement?

Key criteria include documented Ozempic exposure, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy, a temporal relationship between drug use and symptom onset, and exclusion of other causes. Patients who discontinued Ozempic due to gastrointestinal side effects may have stronger claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.